Is DocuSign Stock Undervalued?
Digital signature software business DocuSign (NASDAQ:DOCU) has been struggling over…
Sell
15
UTMD Quote, Financials, Valuation and Earnings
Last price:
$56.64
Seasonality move
:
3.16%
Day range:
$56.29 - $56.67
52-week range:
$51.26 - $65.56
Dividend yield:
2.18%
P/E ratio:
15.93x
P/S ratio:
4.79x
P/B ratio:
1.53x
Volume:
3.7K
Avg. volume:
16.1K
1-year change:
-8.37%
Market cap:
$180.3M
Revenue:
$40.9M
EPS (TTM):
$3.53
Analysts' Opinion
-
Consensus RatingNo consensus rating exists at this time due to lack of analyst coverage.
-
Price Target DownsideNo price target exists because of limited analyst coverage.
-
Price Target UpsideSimilarly, at this time, analysts have not provided a price target so downside risk can't be assessed accurately at this time.
Fair Value
-
According to the consensus of 0 analysts, Utah Medical Products, Inc. has -- downside to fair value with a price target of -- per share.
UTMD vs. S&P 500
-
Over the past 5 trading days, Utah Medical Products, Inc. has underperformed the S&P 500 by -3.23% suggesting its relative strength compared to the major market average is weak at this time.
Share Buyback
-
Utah Medical Products, Inc. does have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
Utah Medical Products, Inc. revenues have been falling on a year-over-year basis for 10 quarters in a row. In the most recent quarter Utah Medical Products, Inc. reported revenues of $9.8M.
Earnings Growth
-
Utah Medical Products, Inc. earnings have been falling on a year-over-year basis for 9 quarters in a row. In the most recent quarter Utah Medical Products, Inc. reported earnings per share of $0.82.
Enterprise value:
96.3M
EV / Invested capital:
0.81x
Price / LTM sales:
4.79x
EV / EBIT:
8.10x
EV / Revenue:
2.49x
PEG ratio (5yr expected):
--
EV / Free cash flow:
6.94x
Price / Operating cash flow:
13.33x
Enterprise value / EBITDA:
6.48x
Gross Profit (TTM):
$20M
Return On Assets:
9.41%
Net Income Margin (TTM):
30.08%
Return On Equity:
9.78%
Return On Invested Capital:
9.75%
Operating Margin:
26.61%
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-09-30 | 2024-09-30 | 2025-09-30 | 2024-09-30 | 2025-09-30 | |
| Income Statement | ||||||
| Revenue | $51.5M | $44.1M | $38.6M | $10M | $9.8M | |
| Gross Profit | $24.9M | $23.5M | $20M | $5.3M | $5.1M | |
| Operating Income | $17.9M | $14.6M | $11.9M | $3.3M | $2.6M | |
| EBITDA | $25M | $17.8M | $14.9M | $4.1M | $3.4M | |
| Diluted EPS | $4.65 | $4.28 | $3.53 | $1.02 | $0.82 | |
| Period Ending | 2021-09-30 | 2022-09-30 | 2023-09-30 | 2024-09-30 | 2025-09-30 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | $75.8M | $84.2M | $101.8M | $101.7M | $96.5M | |
| Total Assets | $119.8M | $118.4M | $131.2M | $129.7M | $122M | |
| Current Liabilities | $5M | $6.3M | $4.2M | $3.4M | $3M | |
| Total Liabilities | $9.8M | $10.2M | $7.5M | $5.5M | $3.7M | |
| Total Equity | $110M | $108.2M | $123.7M | $124.2M | $118.3M | |
| Total Debt | $343K | $354K | $305K | $299K | $241K | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-09-30 | 2024-09-30 | 2025-09-30 | 2024-09-30 | 2025-09-30 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | $22.6M | $17.2M | $14.2M | $3.9M | $3.9M | |
| Cash From Investing | -$587K | -$289K | -$271K | -$89K | -$27K | |
| Cash From Financing | -$4M | -$17.2M | -$18.1M | -$4.9M | -$1.6M | |
| Free Cash Flow | $22M | $16.9M | $13.9M | $3.8M | $3.9M | |
UTMD
Sector
Market Cap
$180.3M
$28M
Price % of 52-Week High
85.86%
51.03%
Dividend Yield
2.18%
0%
Shareholder Yield
8.91%
-1.54%
1-Year Price Total Return
-8.37%
-17.48%
Beta (5-Year)
0.327
0.518
Dividend yield:
2.18%
Annualized payout:
$1.21
Payout ratio:
37.18%
Growth streak:
2 years
Technicals
8-day SMA
Sell
Level
$57.14
200-day SMA
Sell
Level
$57.21
Bollinger Bands (100)
Sell
Level
56.15 - 61.99
Chaikin Money Flow
Sell
Level
-16.8K
20-day SMA
Sell
Level
$56.51
Relative Strength Index (RSI14)
Sell
Level
46.43
ADX Line
Sell
Level
29.46
Williams %R
Neutral
Level
-77.2554
50-day SMA
Sell
Level
$57.18
MACD (12, 26)
Buy
Level
14.92
25-day Aroon Oscillator
Buy
Level
68
On Balance Volume
Sell
Level
-20.3K
Financial Scores
Buy
Altman Z-Score
(Annual)
Level (27.2088)
Buy
CA Score
(Annual)
Level (2.2862)
Sell
Beneish M-Score
(Annual)
Level (-2.1799)
Buy
Momentum Score
Level (3)
Buy
Ohlson Score
Level (-9.51)
Buy
Piotroski F Score
(Annual)
Level (7)
Buy
Quality Ratio Score
Level (6)
Buy
Fundamental Score
Level (10)
Revenue Forecast
Earnings per Share Forecast
Company Profile
Utah Medical Products, Inc. engages in the manufacturing, developing, and marketing of disposable and reusable medical devices. It focuses on the healthcare of women and babies. The firm's products are used for blood pressure monitoring and blood collection, electrosurgery, gynecology, neonatal critical care, perinatology, and urology. The company was founded on April 21, 1978 and is headquartered in Midvale, UT.
Stock Forecast FAQ
In the current month, UTMD has received 0 Buy ratings 0 Hold ratings, and 0 Sell ratings. The UTMD average analyst price target in the past 3 months is --.
-
Where Will Utah Medical Products, Inc. Stock Be In 1 Year?
According to analysts, the consensus estimate is that Utah Medical Products, Inc. share price will drop to -- per share over the next 12 months.
-
What Do Analysts Say About Utah Medical Products, Inc.?
Analysts are divided on their view about Utah Medical Products, Inc. share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that Utah Medical Products, Inc. is a Sell and believe this share price will rise from its current level to --.
-
What Is Utah Medical Products, Inc.'s Price Target?
The price target for Utah Medical Products, Inc. over the next 1-year time period is forecast to be -- according to 0 Wall Street analysts, 0 of them rate the stock a Buy, 0 rate the stock a Sell, and 0 analysts rate the stock a Hold.
-
Is UTMD A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for Utah Medical Products, Inc. is a --. 0 of 0 analysts rate the stock a -- at this time.
-
How Can I Buy Shares Of UTMD?
You can purchase shares of Utah Medical Products, Inc. via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase Utah Medical Products, Inc. shares.
-
What Is The Utah Medical Products, Inc. Share Price Today?
Utah Medical Products, Inc. was last trading at $56.64 per share. This represents the most recent stock quote for Utah Medical Products, Inc.. Yesterday, Utah Medical Products, Inc. closed at $56.29 per share.
-
How To Buy Utah Medical Products, Inc. Stock Online?
In order to purchase Utah Medical Products, Inc. stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
Get UTMD Stock Alert
Signup to receive the latest stock alerts
Financial Ratios
UTMD
Sector
P/E ratio
15.93x
23.89x
PEG ratio
--
-0.01x
P/B ratio
1.53x
1.82x
Price / LTM sales
4.79x
1.60x
Growth Metrics
UTMD
Sector
Revenue growth
-1.93%
4.62%
Earnings growth
-19.91%
10.88%
Revenue (5-year growth)
-2.7%
6.5%
Earnings forecast
--
-$0.21
Profitability
UTMD
Sector
Profitability FY 2024
$22.1M
$3.5M
Return on invested capital
9.75%
-31.77%
Return on assets
9.41%
-27.96%
Return on equity
9.78%
-37.63%
Earnings Date
Last Earnings Date
Oct
23
Next Earnings Date
Jan
27
Estimated Next Earnings Date
Jan
22
Balance Sheet
UTMD
Sector
Total cash
$84.3M
$26.3M
Short term investments
--
$25.7M
Total assets
$122.5M
$78M
Long term debt
$241K
$3.3M
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Is SentinelOne Stock Undervalued?
Cybersecurity major SentinelOne (NYSE:S) has struggled over several years, delivering…
Is Broadcom Stock on Sale?
Chip and software maker Broadcom (NASDAQ:AVGO) has been among the…
Stock Ideas
Buy
57
Is NVDA Stock a Buy?
Market Cap: $4.6T
P/E Ratio: 64x
Buy
55
Is AAPL Stock a Buy?
Market Cap: $4T
P/E Ratio: 37x
Buy
61
Is GOOG Stock a Buy?
Market Cap: $3.8T
P/E Ratio: 39x
Alerts
Buy
80
TVTX alert for Dec 25
Travere Therapeutics, Inc. [TVTX] is up 14.03% over the past day.
Buy
68
KOD alert for Dec 25
Kodiak Sciences, Inc. [KOD] is up 13.41% over the past day.
Buy
64
ZCSH alert for Dec 25
Grayscale Zcash Trust (ZEC) [ZCSH] is up 5.33% over the past day.
THE #1 STOCK ANALYSIS TOOL
TO MAKE SMARTER BUY AND SELL DECISIONS
Show me the best stock
